The present study shows that the altered expression level of TSPX could be correlated with upregulation of various cancer-drivers/oncogenes and repressions of tumor suppressors in both LNCaP cell line and clinical prostate cancer samples in a dosage dependent manner (Figure 5 and Supplementary Table 6). The gene discussed is TSPYL2; the disease is prostate cancer.